Press Releases AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Real-time Estimate Cboe BZX Other stock markets 02:07:21 2024-06-06 pm EDT			5-day change	1st Jan Change
6.455 ^USD	-0.69%		+3.51%	-17.22%

May. 21	AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System	MT
May. 06	AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System	May. 21	BU
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions	May. 06	BU
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results, Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	Apr. 05	AQ
AngioDynamics Receives 510(k) Clearance for AlphaVac F18 System in Treatment of PE	Apr. 05	AQ
AngioDynamics: Fiscal Q3 Earnings Snapshot	Apr. 04	AQ
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	Apr. 04	BU
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	Apr. 04	BU
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.	Apr. 01	BU
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024	Mar. 19	BU
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference	Mar. 06	BU
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million	Feb. 15	BU
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease	Jan. 23	BU
Greenbrier, Constellation Brands rise; AngioDynamics, Agilon Health fall, Friday, 1/5/2024	Jan. 05	AQ
AngioDynamics: Fiscal Q2 Earnings Snapshot	Jan. 05	AQ
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance	Jan. 05	BU
AngioDynamics to Present at the J.P. Morgan Healthcare Conference	Dec. 21	BU
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F18 System in Treatment of Pulmonary Embolism	Dec. 08	AQ
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024	Dec. 07	BU
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism	Dec. 07	BU
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results, Reaffirms Fiscal Year 2024 Guidance	23-10-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Press Releases

Filters